Summary

Results of the first randomized trial to address optimal antiplatelet therapy in patients on oral anticoagulants (OACs) undergoing coronary stenting showed that treatment with dual antithrombotic therapy (OAC plus clopidogrel alone) caused less bleeding than triple antithrombotic therapy (OAC plus aspirin plus clopidogrel), with no excess of thrombotic/thromboembolic events and less all-cause mortality. This article discusses the What Is the Optimal Antiplatelet and Anticoagulant Therapy in Patients with Oral Anticoagulation and Coronary Stenting [WOEST; NCT00769938] trial.